Persista Bio Inc

Persista Bio® technology breaks through prior cell therapy roadblocks and enables implantable cell therapies—it avoids rejection and supports the long-term health of the cells. Preclinical data has already shown success in Type 1 Diabetes. Persista Bio’s O2Line™ system includes: 1) a unique anti-fibrotic cell capsule which prevents immune rejection of the device and enables quick diffusion of the therapeutic, and 2) an in-situ oxygen generator to support the densely packed, macroencapsulated cells. This system will replace conventional therapies (injections, pumps, finger sticks) and enable advanced stem cell therapies without requiring immunosuppression. Persista Bio is a seed stage company licensing technology from Cornell University and Giner, Inc. Founded by Minglin Ma, PhD; Linda Tempelman, PhD; James Flanders, DVM; Brian Pham, PhD. Please follow us on LinkedIn and join our mailing list: info@PersistaBio.com